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INTRODUCTION
Otitis media with effusion (OME) has a multifactorial pathogen-
esis. OME can occur during the resolution of acute otitis media
once the acute inflammation has resolved. The classic explanation
proposes that dysfunction of the Eustachian tube is the necessary
precursor for OME. The dysfunction can be caused a number of
circumstances, including anatomic blockage, inflammation secon-
dary to upper respiratory tract infection, allergies and trauma.
Once the acute inflammation and bacterial infection have resol-
ved, failure of the middle ear’s clearance mechanism allows the
middle ear effusion to persist. Dysfunction of the Eustachian tube
has long been suggested to be a predisposing factor for the failure
of the middle ear’s clearance mechanism (1).
The presence of the surfactant in the Eustachian tube and mi-
ddle ear effusions in humans has been confirmed after the possible
existence of surfactants in the function of the Eustachian tube was
suggested (2-6). Exogenous natural (7-9) and synthetic (10-12)
surfactant preparations can reduce the passive opening pressure
(POP), which is the pressure required to force the Eustachian
tube open. Over 90% of the known surfactants are phospho-
lipids whose chemical structure possesses both a hydrophilic and
hydrophobic character in different regions of the compounds. Of
these phospholipids, dipalmitoylphospatidylchloine comprises
50% of the relevant pulmonary surfactants, with the protein
surfactants comprising the remaining 10%. In addition to their
Objectives. In this study, we evaluated the efficacy of nebulized bovine pulmonary surfactant on experimentally induced
otitis media with effusion (OME) in guinea pigs.
Methods. Twenty guinea pigs were divided into three groups. Four untreated animals served as normal controls. Experi-
mental OME was established in both ears of the remaining 16 animals by a transbullar injection of 10 mL of Pseudo-
monas aeruginosa lipopolysaccharide in saline. Thereafter, the guinea pigs received nebulized phosphate buffered
saline (n=8) or nebulized bovine pulmonary surfactant (n=8). Nebulization was given daily for 7 days. On day 8,
all the animals’ passive opening pressure (POP) of the Eustachian tube was measured and histopathological obser-
vations of the bulla were made by light microscopy.
Results. Nebulized bovine pulmonary surfactant significantly reduced the POP compared to that of saline nebulization.
The bovine pulmonary surfactant improved the tubal patency and produced less histopathologcally-evident edema-
tous bullar mucosa.
Conclusion. Nebulization of bovine pulmonary surfactant plays an important role in treating otitis media with effusion
in guinea pigs. Our results suggest that the chosen nebulized bovine pulmonary surfactant can be of good clinical
benefit for treating OME in the future.
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display host defense capacities. Surfactant associated protein
(SP), and especially SP-A and SP-D, has immune modulating
properties (13-15). Intranasally-metered dose inhalation of aero-
solized synthetic surfactant is effective in reducing the Eustachian
tube POP (10-12), but the synthetic surfactants lack SPs. Alth-
ough clinical trials have demonstrated that both synthetic sur-
factants and natural pulmonary surfactant preparations are effec-
tive to relieve lung disease, comparisons in animal models has
suggested that the natural surfactant products may provide grea-
ter efficacy, and perhaps this is due to their protein content (16). 
Two previous studies (8, 9) using animal models of induced
OME have reported that nebulized surfactants improve the Eus-
tachian tube function. While the results were encouraging, the
small number of studies makes evaluating the significance of the
results somewhat tenuous. As well, one of the studies suffered
from a lack of a control (8), while in the other study the change
of the middle ear pressure was observed by using a tympanome-
ter with a 220 Hz probe tone instead of measuring the POPs of
the Eustachian tube (9). Because the length and volume of the ex-
ternal ear canal and the middle ear of small animals are different
from humans, the relevance of determining the maximal ampli-
tudes by using a tympanometer with a 220 Hz probe tone is ques-
tionable (17). Moreover, the resonant frequency of the middle ear
in guinea pigs and rats is higher than that in humans (18). 
To better relate the results from animal models to human OME,
we evaluated the efficacy of a nebulized natural bovine pulmonary
surfactant in experimental OME by measuring the POP and per-
forming light microscopy histopathologic examination of the bulla
mucosa. 
MATERIALS AND METHODS
Twenty male guinea pigs (250-300 g) with normal eardrums and
normal Preyer reflexes were used for the experiment. They were
housed separately in sterile cages. The animals were divided into
three groups. Four guinea pigs that were untreated served as the
normal controls. The remaining 16 guinea pigs were used to esta-
blish experimental OME in both ears by the transbullar injection
of 10 mL of Pseudomonas aeruginosa lipopolysaccharide (LPS, 1
mg/mL; Sigma-Aldrich, St. Louis, MO, USA) in saline with using
a 25-gauge needle via a postauricular approach. There were no
constitutional symptoms in any animals after the transbullar in-
jection of LPS. On the third day, the animals were anesthetized
using a mixture of ketamine hydrochloride (40 mg/kg) and xyla-
zine hydrochloride (8 mg/kg) that was administered intramuscu-
larly. The presence of OME was confirmed in all the animals as
a clouded, bulging tympanic membrane and the presence of mid-
dle ear effusion on a otomicroscopic examination. The experimen-
tal group 1 (n=8) was then nebulized with 5 mL/day of phosphate
buffered saline (PBS) and the experimental group 2 (n=8) was ne-
bulized with 240 mg of a natural bovine pulmonary surfactant/
280 mL saline (Newfactant, Yuhan, Seoul, Korea). The experi-
mental animals received nebulized bovine surfactant every 60
min for 7 successive days. The dose of surfactant solution used
for nebulization each time was 5 mL/5 mg. Nebulization was
performed by use of a nebulizer (NE-C29, Omron, Kyoto, Japan).
Nebulization was repeated daily for 7 days in both experimental
groups. 
Thermal myringotomy using a 1 mm bovie tip (ITS, Seoul,
Korea) at the anterior quadrant of the tympanic membrane was
done. The baseline POP measurements were made by a modifi-
cation of a previously described technique (2). A 6F latex Foley
catheter (Lifetech, Seoul, Korea) was inserted to the external
auditory canal of each ear. An air-tight seal was created in each
canal by inflation of the balloon. The Foley catheter was then
connected to an air infusion pump and a pressure transducer
(AD Instruments, Castle Hill, Australia) by use of a three-way
connector. The middle ear cavity was inflated by a constant
infusion of air (20 mL/min) via a syringe connected to the infu-
sion pump. The POP was recorded in millimeters of mercury
(mm Hg). The pressure transducer was connected to a Grass
Quad Model 15LT amplifier (Grass Technologies, West Warwick,
RI, USA), and the pressure signals were recorded using a Power-
Lab computerized data acquisition system (AD Instruments) (Fig.
1). The POPs were compared by the Mann-Whitney U-test. Sta-
tistical significance was set at P-values less than 0.05. 
The temporal bone was dissected from the skull, denuded of
adhering tissues and then further processed for light microscopy.
The temporal bones harvested from each animal were preserved
in 4% paraformaldehyde solution for 24 hr and then they were
placed in RapidCal
TM decalcifying solution (BBC Biochemical
Co, Washington, USA) for 2 days. Each paraffin-embedded spe-
cimen was then sectioned and the sections were stained with he-
matoxylin and eosin. 
RESULTS
After the thermal myringotomy for measuring the POP, the mid-
dle ear cavity was observed by otomicroscopic examination. In the
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Fig. 1. Passive opening pressure (POP) measurement in the guinea
pig Eustachian tube. Schematic view of measuring the POP.
Data acquisition computer
Pressure sensor Airtight seal by 6F Foley catheter
Infusion pump Perforated TM E-tubeexperimental group 1, mucosal thickening with effusions on the
epithelial surface were observed. However, no effusion and a nor-
mal gross appearance of the middle ear epithelium were observed
in the surfactant nebulized group. 
All the OME models produced a POP and the threshold of the
POP was similar to that of the PBS nebulized group. The POPs of
the normal control group were similar (18.2 mmHg), while that
of the experimental group 1 animals (68.4 mmHg) was significan-
tly greater. However, the group 2 animals who received the nebu-
lized natural bovine pulmonary surfactant displayed POPs (25.3
mmHg) that were significantly lower than the POPs of the PBS
nebulized experimental group 1 animals (P<0.05) (Figs. 2, 3).
The subepithelial layer of the bullar mucosa of the experimental
group 1 animals was thickened with inflammatory cells. How-
ever, the group 2 animals generally showed less edema and reduced
subepithelial thickening (Fig. 4). 
DISCUSSION
The present study evaluated the efficacy of nebulized natural bo-
vine pulmonary surfactant on experimentally induced OME. In
this study, we used guinea pigs instead of rats because of the high
incidence of natural otitis media in rats. The high incidence of na-
tural otitis media in rats may be related to its small auditory bulla
and horizontal Eustachian tube. It is well established that humans
with small middle ear cavities, a more horizontal Eustachian tube
and a greater density of goblet cells are prone to otitis (19, 20).
Yoon et al. (21) reported on the distribution of elastic fibers in the
Eustachian tubes of rats. The tubal cartilage has a considerable
content of elastic tissue in all regions. The mesh of elastic fibers
of the rat Eustachian tube is most abundant at the hinge portion
and the density gradually decreases in the middle portion. These
finding suggest that elastic fibers may play an important role on
the closure of the Eustachian tube following its opening by con-
traction of the tensor veli palatini muscle.
Nebulization with natural bovine pulmonary surfactant marke-
dly reduced the POP of the guinea pigs with OME compared to
that of the the guinea pigs with OME and who received nebulized
PBS. Our results can be explained by the improved Eustachian
tubal function by the phospholipids and an anti-inflammatory
effect by the protein constituent of the natural bovine pulmonary
surfactant. However, nebulized PBS failed to show any beneficial
effect. In this study, we administered the natural surfactant by
Jang CH et al.: Nebulized Bovine Surfactant for OME 15
Fig. 2. Computerized recording of the passive opening pressure
(POP). (A) Normal control group, (B) Phosphate buffered saline neb-
ulized group, (C) surfactant nebulized group. The asterisk represents
the POP of the nebulization with natural surfactant group.
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Fig. 3. Effects of nebulization with natural surfactant. The use of nebu-
lized natural surfactant in the guinea pigs with otitis media with effu-
sion produced passive opening pressures (POPs) that were signifi-
cantly lower than the POPs resulting from the nebulization of phos-
phate buffered saline (PBS; *P<0.05). LPS: lipopolysaccharide.
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*transnasal nebulization. Approximately 90% of the natural sur-
factant complex in the Eustachian tube is composed of phospho-
lipids. The proteins that make up the remaining 10% are SP-A,
SP-B, SP-C, and SP-D. SP-A and SP-D opsonize, aggregate and
enhance phagocytosis of microbes by the resident macrophages
(22-24), and they may also directly kill bacteria by permeabiliz-
ing their bacterial membranes (25). SP-B was recently shown to
share features with antimicrobial peptides, and native SP-B isolat-
ed from human bronchioalveolar lavage fluid was demonstrated
to kill clinical isolates of gram-positive and gram-negative bacte-
ria in a dose-dependent manner (26). Inhalation delivery of an
aerosolized metered dose of synthetic surfactant comprised of
phospholipid and protein is effective in reducing the POPs in ani-
mals with OME or acute otitis media (10-12). The primary func-
tion of the synthetic surfactant is obviation of adhesion (12). There-
fore, based on the present results, a natural surfactant would seem
to be a more desirable choice when compared to the currently
available synthetic surfactants. 
The advantage of transnasal nebulization is the noninvasive
access to the middle ear, without the necessity of performing my-
ringotomy. Nebulization enables the delivery of a high concen-
tration of the therapeutic agent to the topical mucosa. In one stu-
dy, nebulized antibiotic was not detected in the serum in most
cases after nebulization via the nose (27), which may result in a
lower incidence or absence of general side effects due to the nebu-
lized drug. In this study, none of the guinea pigs experienced visi-
ble discomfort during nebulization. 
Nebulization of natural bovine pulmonary surfactant plays an
important role in treating otitis media with effusion in guinea pigs.
It is effective in reducing the Eustachian tube’s passive opening
pressure and the edematous inflamed bullar mucosa. Our results
suggest that the chosen nebulized natural surfactant can be of cli-
nical benefit for treating OME in the future. 
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